SGM
NKTR icon

Seven Grand Managers’s Nektar Therapeutics NKTR Stock Holding History

Seven Grand Managers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Buy
240,000
+115,000
+92% +$8.41M 0.67% 32
2026
Q1 		$8.99M Buy
+125,000
New +$7.12M 0.6% 35

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Seven Grand Managers's NKTR Position: Q2 2026 in Review

Seven Grand Managers increased its Nektar Therapeutics (NKTR) stake by 92% in Q2 2026, buying an estimated $8.41M and bringing the position to 240,000 shares worth $16.8M. The position accounts for 0.67% of the portfolio, ranked #32.

Seven Grand Managers first reported a position in NKTR in Q1 2026 and has held it in 2 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Seven Grand Managers held 240,000 shares of Nektar Therapeutics worth $16.8M as of Q2 2026.
  • Seven Grand Managers bought 115,000 Nektar Therapeutics shares in Q2 2026, an estimated $8.41M.
  • Nektar Therapeutics made up 0.67% of Seven Grand Managers's portfolio in Q2 2026, its #32 holding.
  • Seven Grand Managers first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.